UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049483
Receipt number R000056348
Scientific Title The optimal target for acute glycemic control in critically ill patients: update systematic review
Date of disclosure of the study information 2022/11/12
Last modified on 2023/05/14 09:06:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The optimal target for acute glycemic control in critically ill patients: update systematic review

Acronym

The optimal target for acute glycemic control in critically ill patients: update systematic review

Scientific Title

The optimal target for acute glycemic control in critically ill patients: update systematic review

Scientific Title:Acronym

The optimal target for acute glycemic control in critically ill patients: update systematic review

Region

Japan


Condition

Condition

Critically ill patients.

Classification by specialty

Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

What is optimal glucose level in critically ill patients?

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Long-term mortality (more than 60 days), 28 or 30 days mortality, and in-hospital mortality.

Key secondary outcomes

Incidences of hypoglycemia (defined as blood glucose levels of <40 mg/dL or hypoglycemia-associated symptoms), sepsis and bloodstream infection.


Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Randomized controlled trials.
2) Adult patients who were treated in the Intensive Care Unit.
3) One of the following blood glucose targets: <110, 110-144, 144-180, >180 (mg/dL) vs One of the other targets other than the target included in intervention
4) Japanese or English

Key exclusion criteria

Conference abstract

Target sample size



Research contact person

Name of lead principal investigator

1st name Tomoaki
Middle name
Last name Yatabe

Organization

Nishichita General Hospital

Division name

Emergency Department

Zip code

4778522

Address

3-1-1, Nakanoike, Tokai, Aichi, Japan

TEL

05662335500

Email

yatabe.tomoaki@katch.ne.jp


Public contact

Name of contact person

1st name Tomoaki
Middle name
Last name Yatabe

Organization

Nishichita General Hospital

Division name

Emergency Department

Zip code

4778522

Address

3-1-1, Nakanoike, Tokai, Aichi, Japan

TEL

0562335500

Homepage URL


Email

yatabe.tomoaki@katch.ne.jp


Sponsor or person

Institute

Guideline committee of The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Not applicable

Address

Not applicable

Tel

Not applicable

Email

Not applicable


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 11 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2022 Year 11 Month 05 Day

Date of IRB

2022 Year 11 Month 05 Day

Anticipated trial start date

2022 Year 11 Month 12 Day

Last follow-up date

2023 Year 02 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Data extraction
The abstracted data for each study included the first author's name, year of publication, number of study sites, number of patients, ICU setting, age, history of diabetes, target blood glucose levels, mean glucose levels during the study period, presence of a protocol, method of glucose measurement, duration of the study, and the mean length of stay in the ICU.

Risk of bias assessment
We will assess risk of bias using RoB2.

Strategy for data synthesis
We will perform the network meta-analysis (random effect) within a Bayesian framework using JAGS, R software, and the rjags and gemtc packages.


Management information

Registered date

2022 Year 11 Month 12 Day

Last modified on

2023 Year 05 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056348


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name